drugset / Trial / NCT04774107
The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
NaSingle-groupOpen-labelOther
Summary
Primary Objective: To determine the P1101 pharmacokinetic (PK) profile at the single dose of 400 μg.
Timeline
- Start
- 2020-11-26
- Primary completion
- 2022-07-18
- Completion
- 2022-07-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ropeginterferon alfa-2b | Protein / enzyme biologic | 400 ug | Subcutaneous |
| Background | Ribavirin | Small molecule | 800 mg | Oral |
| Background | Ribavirin | Small molecule | 1400 mg | Oral |